NMR-based drug development and improvement against malignant melanoma – Implications for the MIA protein family

Oliver Arnolds, Xueyin Zhong, King Tuo Yip, Miriam Schöpel, Bastian Kohl, Stefanie Pütz, Raid Abdel-Jalil, Raphael Stoll

Research output: Contribution to journalReview article

Abstract

The Melanoma Inhibitory Activity (MIA) protein is strongly expressed and secreted by malignant melanoma cells and was shown to promote melanoma development and invasion. The MIA protein was the first extracellular protein shown to adopt an Src homology 3 (SH3) domain-like fold in solution that can bind to fibronectin type III domains. Together with MIA, the homologous proteins OTOR (or FDP), MIA-2, and TANGO (or MIA-3) constitute a protein family of non-cytosolic and – except for full-length TANGO and TANGO1-like (TALI) – extracellular SH3-domain containing proteins. Members of this protein family modulate collagen maturation and export, cartilage development, cell attachment in the extracellular matrix, and melanoma metastasis. These proteins may thus serve as promising targets for drug development against malignant melanoma. For the last twenty years, NMR spectroscopy has become a powerful technique in medicinal chemistry. While traditional high throughput screenings only report on the activity or affinity of low molecular weight compounds, NMR spectroscopy does not only relate to the structure of those compounds with their activity, but it can also unravel structural information on the ligand binding site on the protein at atomic resolution. Based on the molecular details of the interaction between the ligand and its target protein, the binding affinities of initial fragment hits can be further improved more efficiently in order to generate lead structures that exhibit significant therapeutic effects. The NMR-based approach promises to greatly contribute to the quest for low molecular weight compounds that ultimately could yield drugs to treat skin-related diseases such as malignant melanoma more effectively.

Original languageEnglish
Pages (from-to)1788-1796
Number of pages9
JournalCurrent Medicinal Chemistry
Volume24
Issue number17
DOIs
Publication statusPublished - 2017

Fingerprint

Melanoma
Nuclear magnetic resonance
Pharmaceutical Preparations
Proteins
src Homology Domains
Nuclear magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Molecular Weight
Molecular weight
Ligands
Pharmaceutical Chemistry
Cartilage
Therapeutic Uses
Fibronectins
Skin Diseases
Protein Binding
Extracellular Matrix
Skin
Screening
Collagen

Keywords

  • Antibiotics
  • FBLS
  • FDP
  • MIA
  • NMR
  • SH3
  • TANGO

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

NMR-based drug development and improvement against malignant melanoma – Implications for the MIA protein family. / Arnolds, Oliver; Zhong, Xueyin; Yip, King Tuo; Schöpel, Miriam; Kohl, Bastian; Pütz, Stefanie; Abdel-Jalil, Raid; Stoll, Raphael.

In: Current Medicinal Chemistry, Vol. 24, No. 17, 2017, p. 1788-1796.

Research output: Contribution to journalReview article

Arnolds, Oliver ; Zhong, Xueyin ; Yip, King Tuo ; Schöpel, Miriam ; Kohl, Bastian ; Pütz, Stefanie ; Abdel-Jalil, Raid ; Stoll, Raphael. / NMR-based drug development and improvement against malignant melanoma – Implications for the MIA protein family. In: Current Medicinal Chemistry. 2017 ; Vol. 24, No. 17. pp. 1788-1796.
@article{fe72fbba209d4e479b1a144cf999aeb3,
title = "NMR-based drug development and improvement against malignant melanoma – Implications for the MIA protein family",
abstract = "The Melanoma Inhibitory Activity (MIA) protein is strongly expressed and secreted by malignant melanoma cells and was shown to promote melanoma development and invasion. The MIA protein was the first extracellular protein shown to adopt an Src homology 3 (SH3) domain-like fold in solution that can bind to fibronectin type III domains. Together with MIA, the homologous proteins OTOR (or FDP), MIA-2, and TANGO (or MIA-3) constitute a protein family of non-cytosolic and – except for full-length TANGO and TANGO1-like (TALI) – extracellular SH3-domain containing proteins. Members of this protein family modulate collagen maturation and export, cartilage development, cell attachment in the extracellular matrix, and melanoma metastasis. These proteins may thus serve as promising targets for drug development against malignant melanoma. For the last twenty years, NMR spectroscopy has become a powerful technique in medicinal chemistry. While traditional high throughput screenings only report on the activity or affinity of low molecular weight compounds, NMR spectroscopy does not only relate to the structure of those compounds with their activity, but it can also unravel structural information on the ligand binding site on the protein at atomic resolution. Based on the molecular details of the interaction between the ligand and its target protein, the binding affinities of initial fragment hits can be further improved more efficiently in order to generate lead structures that exhibit significant therapeutic effects. The NMR-based approach promises to greatly contribute to the quest for low molecular weight compounds that ultimately could yield drugs to treat skin-related diseases such as malignant melanoma more effectively.",
keywords = "Antibiotics, FBLS, FDP, MIA, NMR, SH3, TANGO",
author = "Oliver Arnolds and Xueyin Zhong and Yip, {King Tuo} and Miriam Sch{\"o}pel and Bastian Kohl and Stefanie P{\"u}tz and Raid Abdel-Jalil and Raphael Stoll",
year = "2017",
doi = "10.2174/0929867324666170608104347",
language = "English",
volume = "24",
pages = "1788--1796",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "17",

}

TY - JOUR

T1 - NMR-based drug development and improvement against malignant melanoma – Implications for the MIA protein family

AU - Arnolds, Oliver

AU - Zhong, Xueyin

AU - Yip, King Tuo

AU - Schöpel, Miriam

AU - Kohl, Bastian

AU - Pütz, Stefanie

AU - Abdel-Jalil, Raid

AU - Stoll, Raphael

PY - 2017

Y1 - 2017

N2 - The Melanoma Inhibitory Activity (MIA) protein is strongly expressed and secreted by malignant melanoma cells and was shown to promote melanoma development and invasion. The MIA protein was the first extracellular protein shown to adopt an Src homology 3 (SH3) domain-like fold in solution that can bind to fibronectin type III domains. Together with MIA, the homologous proteins OTOR (or FDP), MIA-2, and TANGO (or MIA-3) constitute a protein family of non-cytosolic and – except for full-length TANGO and TANGO1-like (TALI) – extracellular SH3-domain containing proteins. Members of this protein family modulate collagen maturation and export, cartilage development, cell attachment in the extracellular matrix, and melanoma metastasis. These proteins may thus serve as promising targets for drug development against malignant melanoma. For the last twenty years, NMR spectroscopy has become a powerful technique in medicinal chemistry. While traditional high throughput screenings only report on the activity or affinity of low molecular weight compounds, NMR spectroscopy does not only relate to the structure of those compounds with their activity, but it can also unravel structural information on the ligand binding site on the protein at atomic resolution. Based on the molecular details of the interaction between the ligand and its target protein, the binding affinities of initial fragment hits can be further improved more efficiently in order to generate lead structures that exhibit significant therapeutic effects. The NMR-based approach promises to greatly contribute to the quest for low molecular weight compounds that ultimately could yield drugs to treat skin-related diseases such as malignant melanoma more effectively.

AB - The Melanoma Inhibitory Activity (MIA) protein is strongly expressed and secreted by malignant melanoma cells and was shown to promote melanoma development and invasion. The MIA protein was the first extracellular protein shown to adopt an Src homology 3 (SH3) domain-like fold in solution that can bind to fibronectin type III domains. Together with MIA, the homologous proteins OTOR (or FDP), MIA-2, and TANGO (or MIA-3) constitute a protein family of non-cytosolic and – except for full-length TANGO and TANGO1-like (TALI) – extracellular SH3-domain containing proteins. Members of this protein family modulate collagen maturation and export, cartilage development, cell attachment in the extracellular matrix, and melanoma metastasis. These proteins may thus serve as promising targets for drug development against malignant melanoma. For the last twenty years, NMR spectroscopy has become a powerful technique in medicinal chemistry. While traditional high throughput screenings only report on the activity or affinity of low molecular weight compounds, NMR spectroscopy does not only relate to the structure of those compounds with their activity, but it can also unravel structural information on the ligand binding site on the protein at atomic resolution. Based on the molecular details of the interaction between the ligand and its target protein, the binding affinities of initial fragment hits can be further improved more efficiently in order to generate lead structures that exhibit significant therapeutic effects. The NMR-based approach promises to greatly contribute to the quest for low molecular weight compounds that ultimately could yield drugs to treat skin-related diseases such as malignant melanoma more effectively.

KW - Antibiotics

KW - FBLS

KW - FDP

KW - MIA

KW - NMR

KW - SH3

KW - TANGO

UR - http://www.scopus.com/inward/record.url?scp=85026738879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026738879&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170608104347

DO - 10.2174/0929867324666170608104347

M3 - Review article

VL - 24

SP - 1788

EP - 1796

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 17

ER -